Centre de Documentation Campus Montignies
Horaires :
Lundi : 8h-18h30
Mardi : 8h-18h30
Mercredi 9h-16h30
Jeudi : 8h-18h30
Vendredi : 8h-16h30
Lundi : 8h-18h30
Mardi : 8h-18h30
Mercredi 9h-16h30
Jeudi : 8h-18h30
Vendredi : 8h-16h30
Bienvenue sur le catalogue du centre de documentation du campus de Montignies.
Résultat de la recherche
2 résultat(s) recherche sur le mot-clé 'Motor nerve block'
Ajouter le résultat dans votre panier Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
French clinical guidelines for peripheral motor nerve blocks in a PRM setting / Alain P. Yelnik in Annals of physical and rehabilitation medicine, Vol. 62, n°4 (Juillet 2019)
[article]
Titre : French clinical guidelines for peripheral motor nerve blocks in a PRM setting Type de document : texte imprimé Auteurs : Alain P. Yelnik ; Claire Hentzen ; Philippe Cuvillon ; Etienne Allart ; Isabelle V. Bonan ; François C. Boyer ; Flavia Coroian ; Éric Viel (1931-2008) Année de publication : 2019 Article en page(s) : p. 252-264 Note générale : https://doi.org/10.1016/j.rehab.2019.06.001 Langues : Anglais (eng) Mots-clés : Motor nerve block Physical and rehabilitation medicine Spasticity Rehabilitation Résumé : Introduction
Motor nerve blocks with anesthetic drug for local anesthesia are commonly used in physical and rehabilitation medicine (PRM), especially in the field of spasticity. Guidelines in this context are currently lacking.
Method
Eighteen experts selected on the basis of their recognized experience by the scientific committees of the French PRM (SOFMER) and Anesthesia and Intensive care (SFAR) societies were invited to work and propose guidelines for the use of loco-regional anesthetic drug for motor nerve blocks in PRM setting. Eight issues were addressed: which neural blocks for which indications; drugs and contraindications; medical survey and attitude in case of adverse event; injection and guidance material; patient preparation and pain relief; efficacy assessment; patient information; education of PRM physiatrists. The Medline, Cochrane and Embase databases for the period 1999 to 2018 were consulted and 355 papers analyzed. The drafts were commented then approved by the whole group using electronic vote, before final approval by scientific committee of each society.
Results
No scientific evidence emerged from the literature. Thus, these guidelines are mainly based on the opinion of the expert panel. Guidelines for each issue are reported with the main points of arguments. The main question deals with the recommendation about doses for each drug: for lidocaine – up to 2 mg/kg – “check contraindications, emergency truck available, no need of previous anesthetic consultation nor presence of anesthetic physician”; for ropivacaine – up to 1.5 mg/kg, with a maximum of 100 mg – the same but after intravenous line. Beyond these doses, SFAR guidelines have to be applied with the need of anesthetic physician.
Conclusion
These are the first organizational guidelines devoted to increase the security of motor nerve block use in PRM settings.En ligne : https://www.sciencedirect.com/science/article/pii/S1877065719300739 Permalink : ./index.php?lvl=notice_display&id=84130
in Annals of physical and rehabilitation medicine > Vol. 62, n°4 (Juillet 2019) . - p. 252-264[article] French clinical guidelines for peripheral motor nerve blocks in a PRM setting [texte imprimé] / Alain P. Yelnik ; Claire Hentzen ; Philippe Cuvillon ; Etienne Allart ; Isabelle V. Bonan ; François C. Boyer ; Flavia Coroian ; Éric Viel (1931-2008) . - 2019 . - p. 252-264.
https://doi.org/10.1016/j.rehab.2019.06.001
Langues : Anglais (eng)
in Annals of physical and rehabilitation medicine > Vol. 62, n°4 (Juillet 2019) . - p. 252-264
Mots-clés : Motor nerve block Physical and rehabilitation medicine Spasticity Rehabilitation Résumé : Introduction
Motor nerve blocks with anesthetic drug for local anesthesia are commonly used in physical and rehabilitation medicine (PRM), especially in the field of spasticity. Guidelines in this context are currently lacking.
Method
Eighteen experts selected on the basis of their recognized experience by the scientific committees of the French PRM (SOFMER) and Anesthesia and Intensive care (SFAR) societies were invited to work and propose guidelines for the use of loco-regional anesthetic drug for motor nerve blocks in PRM setting. Eight issues were addressed: which neural blocks for which indications; drugs and contraindications; medical survey and attitude in case of adverse event; injection and guidance material; patient preparation and pain relief; efficacy assessment; patient information; education of PRM physiatrists. The Medline, Cochrane and Embase databases for the period 1999 to 2018 were consulted and 355 papers analyzed. The drafts were commented then approved by the whole group using electronic vote, before final approval by scientific committee of each society.
Results
No scientific evidence emerged from the literature. Thus, these guidelines are mainly based on the opinion of the expert panel. Guidelines for each issue are reported with the main points of arguments. The main question deals with the recommendation about doses for each drug: for lidocaine – up to 2 mg/kg – “check contraindications, emergency truck available, no need of previous anesthetic consultation nor presence of anesthetic physician”; for ropivacaine – up to 1.5 mg/kg, with a maximum of 100 mg – the same but after intravenous line. Beyond these doses, SFAR guidelines have to be applied with the need of anesthetic physician.
Conclusion
These are the first organizational guidelines devoted to increase the security of motor nerve block use in PRM settings.En ligne : https://www.sciencedirect.com/science/article/pii/S1877065719300739 Permalink : ./index.php?lvl=notice_display&id=84130 Exemplaires (1)
Cote Support Localisation Section Disponibilité Revue Revue Centre de Documentation HELHa Campus Montignies Armoires à volets Document exclu du prêt - à consulter sur place
Exclu du prêtBotulinum toxin type A or selective neurotomy for treating focal spastic muscle overactivity? / Thierry Deltombe in Annals of physical and rehabilitation medicine, Vol. 62, n°4 (Juillet 2019)
[article]
Titre : Botulinum toxin type A or selective neurotomy for treating focal spastic muscle overactivity? Type de document : texte imprimé Auteurs : Thierry Deltombe ; Thierry Lejeune ; Thierry Gustin Année de publication : 2019 Article en page(s) : p. 220-224 Note générale : https://doi.org/10.1016/j.rehab.2018.07.008 Langues : Anglais (eng) Mots-clés : Hemiplegia Muscle spasticity Motor nerve block Neurotomy Equinovarus foot Résumé : Objective
To discuss the effectiveness, indications, limitations and side effects of botulinum toxin type A and selective neurotomy for treating focal spastic muscle overactivity to help clinicians choose the most appropriate treatment.
Methods
Expert opinion based on scientific evidence and personal experience.
Results
Botulinum toxin type A can decrease muscle tone in different types of spastic muscle overactivity, which allows for treating a large variety of spastic patterns with several etiologies. The toxin effect is sometimes insufficient to improve functional outcome and is transient, thereby requiring repeated injections. Selective neurotomy is a permanent surgical treatment of the reflex component of the spastic muscle overactivity (spasticity) that is effective for spastic equinovarus foot. The neurotomy provides a greater and more constant reduction in spasticity. However, the long-lasting effect on the non-reflex muscle overactivity, especially dystonia, is doubted. The effectiveness, clinical indications, advantages, side effects and limitations of both techniques are discussed.
Conclusion
Botulinum toxin type A has the highest level of evidence and the largest range of indications. However, the botulinum toxin effect is reversible and seems less effective, which supports a permanent surgical treatment such as selective neurotomy, especially for the spastic foot. Further research is needed to compare the effect of botulinum toxin type A and selective neurotomy for the different types of spastic muscle overactivity and clinical patterns.En ligne : https://www.sciencedirect.com/science/article/pii/S1877065718314398 Permalink : ./index.php?lvl=notice_display&id=84126
in Annals of physical and rehabilitation medicine > Vol. 62, n°4 (Juillet 2019) . - p. 220-224[article] Botulinum toxin type A or selective neurotomy for treating focal spastic muscle overactivity? [texte imprimé] / Thierry Deltombe ; Thierry Lejeune ; Thierry Gustin . - 2019 . - p. 220-224.
https://doi.org/10.1016/j.rehab.2018.07.008
Langues : Anglais (eng)
in Annals of physical and rehabilitation medicine > Vol. 62, n°4 (Juillet 2019) . - p. 220-224
Mots-clés : Hemiplegia Muscle spasticity Motor nerve block Neurotomy Equinovarus foot Résumé : Objective
To discuss the effectiveness, indications, limitations and side effects of botulinum toxin type A and selective neurotomy for treating focal spastic muscle overactivity to help clinicians choose the most appropriate treatment.
Methods
Expert opinion based on scientific evidence and personal experience.
Results
Botulinum toxin type A can decrease muscle tone in different types of spastic muscle overactivity, which allows for treating a large variety of spastic patterns with several etiologies. The toxin effect is sometimes insufficient to improve functional outcome and is transient, thereby requiring repeated injections. Selective neurotomy is a permanent surgical treatment of the reflex component of the spastic muscle overactivity (spasticity) that is effective for spastic equinovarus foot. The neurotomy provides a greater and more constant reduction in spasticity. However, the long-lasting effect on the non-reflex muscle overactivity, especially dystonia, is doubted. The effectiveness, clinical indications, advantages, side effects and limitations of both techniques are discussed.
Conclusion
Botulinum toxin type A has the highest level of evidence and the largest range of indications. However, the botulinum toxin effect is reversible and seems less effective, which supports a permanent surgical treatment such as selective neurotomy, especially for the spastic foot. Further research is needed to compare the effect of botulinum toxin type A and selective neurotomy for the different types of spastic muscle overactivity and clinical patterns.En ligne : https://www.sciencedirect.com/science/article/pii/S1877065718314398 Permalink : ./index.php?lvl=notice_display&id=84126 Exemplaires (1)
Cote Support Localisation Section Disponibilité Revue Revue Centre de Documentation HELHa Campus Montignies Armoires à volets Document exclu du prêt - à consulter sur place
Exclu du prêt